直击糖尿病大血管病变 他汀治疗策略之优化.ppt

Issued on 2016 ESC Congress: HIJ-PROPER study-no significant benefits from treatment with statins plus ezetimibe HIJ-PROPER study: 1,734 ACS patients were randomized to receive treatment with pitavastatin plus ezetimibe or treatment with pitavastatin alone, and average follow-up period was 3.9 years. Primary composite endpoints included total death rate, non-fatal myocardial infarction, non-fatal stroke, unstable angina and revascularization due to ischemia events. ESC 2016 Drug Post-treatment LDL-C Primary composite endpoint events P value Pitavastatin 2.26 mmol/L 36.9% 0.152 Pitavastatin +